Does anthracycline administration by infusion in children affect late cardiotoxicity? - Wikidata - awgldk - TriplyDB

Does anthracycline administration by infusion in children affect late cardiotoxicity?

Does anthracycline administration by infusion in children affect late cardiotoxicity?

http://www.wikidata.org/entity/Q44776800

about

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407 Cardiovascular disease in adult survivors of childhood cancer.Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Dexrazoxane as a cardioprotectant in children receiving anthracyclines Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity.A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.Anthracycline cardiotoxicity.Anthracycline cardiotoxicity in childhood.Late effects of childhood leukemia therapy.Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.Treatment-related cardiotoxicity in survivors of childhood cancer.Cardiac complications in childhood cancer survivors treated with anthracyclines.Preventing pediatric cardiomyopathy: a 2015 outlook.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Cardiac functions evaluated with tissue Doppler imaging in childhood cancers treated with anthracyclines.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

P2860

Q24240568-7B18A0C6-D2D6-45F2-BF29-0A841AD7572C Q24243810-68683818-941C-44B2-AB35-5B4371859005 Q24628695-3A8AAAC4-1A7B-4E19-9E11-A34E010C317A Q33270016-619431EB-1753-4646-9EA9-D96D184F2994 Q33559419-9A942F37-60CE-43DF-A808-9D87DF7C46C5 Q34042984-40CE300C-B719-4A95-9ED9-15C240D7E8A4 Q34563378-3FFC1F39-CCB9-44C4-917F-9F672DFD5B0B Q34572109-C9E41549-9FD2-4D42-B81A-E0852CF9940D Q35583768-E60644A5-FA62-4ECC-B3A0-0B164A490444 Q36184665-F7E3AF0F-3B55-4A59-BDC6-771A4AC66339 Q36425761-946656D9-BAB7-4FD7-80C1-5F30206B02BD Q36568908-4036137C-6BF9-4EBE-9C3D-2EC79C392816 Q36590959-78DE835D-3015-40AA-BDE2-0C96D9A245B7 Q36612320-41B34E19-AB3F-4763-A994-9EEB96394CE4 Q36624983-81492AAD-13AF-4A53-8579-ABA171556D76 Q37165394-8F615C99-7F6E-4B64-A103-53FAFB87BE2F Q37892981-B970995F-E6EF-4580-B03C-CF3CAEED92A3 Q38079197-9152FF14-6CDF-42A9-AEDC-4D983BECC5E3 Q38156036-FA5FBDF4-225E-4202-B44B-E1F1461DBF2F Q38588167-9F5CEBA6-BDC5-4A4A-BF90-6B679606DBB4 Q38662111-B78B82B6-81F3-403E-A319-F261A1133A5F Q38838517-757839F7-6092-4ECF-BD3C-A4C336502675 Q43178517-15C9C1B4-55AD-4AFE-8811-DAFBD86CE314 Q45073135-5AC3962D-37ED-459D-B512-27B6275EFABC

P2860

Does anthracycline administration by infusion in children affect late cardiotoxicity?

http://www.wikidata.org/entity/Q44776800

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@en

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@nl

type

label

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@en

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@nl

prefLabel

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@en

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@nl

P1433

Q44776800-3926FCBF-683C-4A93-93C3-F2CD0696175F

P1476

Q44776800-E36B21E5-013E-47F3-A813-8ED148251E72

P2093

Q44776800-50612940-1167-4CF2-9C72-764B4C1E670B

Q44776800-B7F9DBF5-40C1-4996-A3D8-1285E9664D92

Q44776800-CBA760BA-CCB6-4EC7-BFD9-1C5429BF954B

Q44776800-DC4E6920-3F53-4C02-A4D1-477155D81EF1

P2860

Q44776800-23440196-913D-4B99-BEA3-571E938831F7

Q44776800-54B705CD-5301-4825-8A88-605B9C62D122

Q44776800-62BB8003-6318-470A-B547-E08C943B1181

Q44776800-8A1200F1-3D0E-479E-9023-FDA567B4209C

Q44776800-940B77B7-6D9A-4864-8168-65F3FFE46637

Q44776800-A0689050-CB3E-43C3-A810-4C7209AC60CC

Q44776800-A1C43DEC-357B-48F2-AB74-15105AD1B84C

Q44776800-A29F601E-7AFF-40DD-A2F9-A2FC098F5DE5

Q44776800-B50129BD-3393-48BE-B37F-37117563F519

Q44776800-BB0B5312-0A19-4EA7-AD63-925758D9CA5B

P304

Q44776800-FF303802-7948-4840-82A3-57320D3A1EF1

P31

Q44776800-3A50D0CA-CCAC-40B1-A02A-4E434698A882

P356

Q44776800-B81E59A5-1B48-464B-B5A9-C1A6FF6C419B

P407

Q44776800-66E851F9-9F35-4AE8-8D1F-88F6A346BF58

P433

Q44776800-C091769C-EC9E-49A0-AC31-AC64B890E83E

P478

Q44776800-91262D23-BC45-4237-B28D-D052B6BCF5FE

P577

Q44776800-B6236486-D397-4C42-B07C-7ECA4B54184F

P5875

Q44776800-B91F7D6C-1C0F-4B4A-BF23-1F4DE49F1748

P698

Q44776800-6343F09C-4F27-4E36-801B-E0E44690E1AB

P356

J.1365-2141.2004.04803.X

P1433

British Journal of Haematology

P1476

Does anthracycline administration by infusion in children affect late cardiotoxicity?

@en

P2093

Dorup I

http://www.w3.org/2001/XMLSchema#string

Levitt GA

http://www.w3.org/2001/XMLSchema#string

Sorensen K

http://www.w3.org/2001/XMLSchema#string

Sullivan I

http://www.w3.org/2001/XMLSchema#string

P2860

Statistics notes. Treatment allocation in controlled trials: why randomise?

Cardioprotection.

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration?

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.

P304

463-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2004.04803.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8683961

http://www.w3.org/2001/XMLSchema#string

P698

14984495

http://www.w3.org/2001/XMLSchema#string